RTI Biologics® Launches Fortiva™ Porcine Dermis, First Human Implantation Complete

  RTI Biologics® Launches Fortiva™ Porcine Dermis, First Human Implantation
  Complete

Implant Rounds Out Comprehensive Line of Biologic Solutions for Hernia Repair

Business Wire

ALACHUA, Fla. -- June 6, 2013

RTI Biologics Inc. (RTI) (Nasdaq:RTIX), a leading provider of orthopedic and
other biologic implants, is pleased to announce the launch of its Fortiva™
porcine dermis implant at the Abdominal Wall Reconstruction (AWR) Conference
in Washington, D.C., June 6-8. This implant positions RTI as the only provider
with a comprehensive biologic solutions portfolio for use in hernia repair
procedures. Tutopatch™ bovine pericardium, Tutomesh™ fenestrated bovine
pericardium and Cortiva™ allograft dermis launched in March. The company’s
full line of implants is distributed directly by RTI’s Surgical Specialties
business unit.

RTI celebrated a milestone for Fortiva porcine dermis on May 23 when a patient
in Missouri received a 10x16cm graft for an incisional hernia repair using a
component separation technique. Due to the optimal handling characteristics of
the implant, the surgeon and his staff felt the graft was easier to suture
than other implants they have utilized previously, which saved time during
surgery.

Fortiva porcine dermis is a non-crosslinked acellular porcine dermal matrix
intended for use as a soft tissue patch to reinforce soft tissue where
weakness exists and for the surgical repair of damaged or ruptured soft tissue
membranes. The implant is indicated for use in repairing hernias and/or body
wall defects that require the use of reinforcing or bridging material to
obtain the desired surgical outcome. Fortiva porcine dermis is ready-to-use,
requiring no rehydration or rinsing. Fortiva also aids in efficiency in the
OR, with a temperature indicator for quick indication of proper storage,
rounded corners for ease of suturing and consistent thickness. The implant is
available in a broad array of sizes, including 35x35 cm, which represents the
largest biologics graft available today.

Fortiva porcine dermis is sterilized through RTI’s Tutoplast^® Tissue
Sterilization Process, a validated chemical sterilization process that
thoroughly penetrates tissue, removing antigenicity and inactivating
pathogens. Terminal sterilization using low dose gamma irradiation achieves a
sterility assurance level (SAL) of 10^-6.

“The launch of Fortiva porcine dermis is a major milestone for RTI, as we now
offer surgeons the most comprehensive biologic solutions in hernia repair from
a provider they trust,” said Brian K. Hutchison, RTI president and CEO.
“Surgeons know our company’s history of reliability and safety. Fortiva gives
surgeons the strength, sterility, remodeling and revascularization, and
efficiency they are looking for.”

RTI will be exhibiting at booth #100 at AWR. Surgeons will have the
opportunity to handle some of the implants on June 8 during AWR’s Masters
Workshop: Hands-On Cadaver Lab. Fortiva porcine dermis will be featured at the
Component Separation lab station and Tutopatch bovine pericardium will be
featured at the Minimally Invasive lab station.

RTI’s comprehensive line of biologic implants used in hernia repair procedures
is currently available for distribution. For more information, visit
www.RTIbiologics.com or contact an RTI representative at (877) 612-4287.

About RTI Biologics Inc.

RTI Biologics Inc. is a leading provider of sterile biologic implants for
surgeries around the world with a commitment to advancing science, safety and
innovation. RTI prepares human donated tissue and animal tissue for
transplantation through extensive testing and screening, precision shaping and
using proprietary, validated processes. These allograft and xenograft implants
are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for
biologics – from being the first company to offer precision-tooled bone
implants and assembled technology to maximize each gift of donation, to
inventing validated sterilization processes that include viral inactivation
steps. These processes — BioCleanse®, Tutoplast® and Cancelle® SP DBM — have a
combined record of more than five million implants sterilized with zero
incidence of implant-associated infection. These processes have been validated
by tissue type to inactivate or remove viruses, bacteria, fungi and spores
from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with
international locations in Germany and France. The company is accredited by
the American Association of Tissue Banks in the United States and is a member
of AdvaMed.

Contact:

RTI Biologics Inc.
Jenny Highlander, APR, 386-418-8888, Ext. 4149
Manager, Corporate Communications
jhighlander@rtix.com